*Purpose: To analyze the role of low-dose intravenous immunoglobulin (IVIG) united with plasmapheresis in high sensitization renal transplantation recipients.

*Methods: Four patients with high levels of panel reactive antibodies (PRA) before transplantation (group A), 7 patients with delayed renal graft function with high PRA levels (group B) and 8 recipients with humoral rejection with high PRA levels (group C) were enrolled into the observe group ( a total of 19 cases). 17 patients with the same manifestations as the group A, B and C were randomly chosen and enrolled into the control group. In the observe group, the group A, B were treated with plasma exchange (PP) combined with low-dose IVIG continuous intravenous infusion 0.1g/ (kg.d), and the group C was treated with steroid hormone shock combined with small dose IVIG continuous intravenous infusion of 0.1g/(kg·d).In contrast, an equal treatment without IVIG was used in the control group. The differences in PRA levels and patient prognosis were analyzed between the observe group and the control group.

*Results: The decrement of PRA level showed a significant difference between the observe group and the control group. Compared to the control group, the rejection rate after transplantation decreased in the group A,the recovery time of transplanted kidney function reduced in the group B, and serum creatinine decreased in the group C. These results were all statistically significant (p<0.05).

*Conclusions: Low-dose IVIG combined with plasmapheresis could also decrease the PRA level in high sensitization renal transplantation recipients compared to the traditional high-dose treatment. The result had positive significance for the treatment of patients with high PRA levels and could greatly reduce medical costs.

« Back to 2019 American Transplant Congress